In this dose-ranging study , patients ( n = @ ) with active RA , despite methotrexate , were randomly assigned to placebo or one of five subcutaneous doses/regimens of sarilumab : @mg q@w , @mg q@w , @mg qw , @mg q@w , @mg qw for @weeks , plus methotrexate .